Tirzepatide vs Retatrutide: Mechanism, Studies and Dose Differences
Technical comparison between the FDA-approved GLP-1/GIP dual agonist and the Phase III triple agonist setting new weight-loss records.
What is Tirzepatide
Tirzepatide is a synthetic dual-agonist activating GLP-1 and GIP receptors. FDA-approved in 2022 as Mounjaro (T2D) and Zepbound (obesity). Studied in SURMOUNT and SURPASS.
Mechanism: mimics gut incretins released after a meal β glucose-dependent insulin, slowed gastric emptying, reduced appetite. GIP adds adipose tissue effects pure GLP-1 lacks.
What is Retatrutide
Retatrutide is a triple-agonist: GLP-1, GIP and glucagon. Phase 3 β positive 2026 readouts (TRIUMPH-1 ~28% at 80 weeks). NEJM 2023 (Phase 2): up to 24.2% weight loss at 48 weeks with 12 mg β a greater magnitude than reported for Tirzepatide (cross-trial, not a head-to-head study).
Mechanism: why triple beats dual
Glucagon counterintuitively raises hepatic glucose, but at sub-hyperglycemic doses increases thermogenesis and lipolysis. Simultaneous GLP-1 offsets the glycemic effect.
Dose comparison
| Variable | Tirzepatide | Retatrutide |
|---|---|---|
| Receptors | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Status | FDA approved | Phase III |
| Dose range | 2.5β15 mg/wk | 1β12 mg/wk |
| Weight loss (52 wk) | ~20.9% | ~24.2% |
| Half-life | ~5 days | ~6 days |
How to choose
For regulated evidence + safety: Tirzepatide.
For maximum fat-loss ceiling: Retatrutide.
Reconstitution
Both lyophilized. Reconstitute with BAC water. Example: 10 mg vial + 2 mL = 5 mg/mL. Calculator.
Stacks
- 5-Amino-1MQ
- SLU-PP-332
- AOD-9604
- MOTS-c
Related products
Bakri: when a drug name ends in β-tideβ it's a peptide, and the root usually hints at the mechanism. Retatrutide is a triple agonist (GLP-1/GIP/glucagon). Foundation first β sleep, morning sunlight, diet, exercise β peptides are additive only.
Educational context (RUO). Based on βPeptides: The Science, Uses & Safetyβ (Huberman Lab, Jun 2026). Not an endorsement by Dr. Bakri or Dr. Huberman. Watch the episodeβ Research use only. Not medical advice.